EU Pharmaceutical Regulations & Strategy Course: Registration Strategy Discussion - Will Brexit Alter this? (London, United Kingdom - October 31, 2019 November 1, 2019)
This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures, and obligations
You will learn about the legal basis of regulation, development strategies and the strategic importance of pre-submission actions, the format for presentation of data, how the registration procedures work and post-authorisation strategies and obligations.
The programme will be of value to regulatory affairs personnel and also to those who interact with regulatory personnel in order to understand action timelines and information requirements.
Benefits of attending:
Understand the legal basis of the EU regulatory environment
Discuss development strategy and pre-submission activities
Review procedures for applying for an EU marketing authorisation
Discuss post-authorisation strategic considerations and obligations
Who Should Attend:
This course will be of particular relevance if you are involved in:
Regulatory affairs
Project management
Business planning
Commercial management
Manufacturing and QA
Labelling and artwork
Medical information
Clinical
Pharmacovigilance
Agenda:
Programme day one
Welcome and introduction
EU regulatory environment: legal basis
Key regulations, directives and guidelines and information sources
Impact of Brexit
Development strategy and pre-submission activities
Scientific advice
Pediatric use
Case study 1: Submission requirements
The Common Technical Document (CTD)
Structure and content of the CTD
The EMA
Impact of Brexit
Applying for marketing authorisation in the EU
Fast-track, conditional approval, and exceptional circumstances
Adaptive licensing
Centralised procedure (CP)
Case study 2: Registration strategy discussion
Will Brexit alter this?
Programme day two
Registration procedures
Co-ordination group
Decentralised procedure (DCP)
Mutual recognition procedure (MRP)
National procedures
Managing product labelling
Company core data sheets
Updates to SmPC
Abridged applications
Legal basis
Data exclusivity
Generics - definition, and criteria
Post-authorisation obligations and strategic considerations
Safety reporting
Pharmacovigilance
Licence variations
Type I and Type II variations
Strategic considerations
Line extensions
Classification switch
Parallel trade (impact of Brexit)
Phase IV studies
Case study 3: Post-authorisation strategy discussion
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...